Canaccord analyst Elyse Shapiro downgraded Mayne Pharma to Hold from Buy with a price target of A$3.80, down from A$7.40. The analyst sees a lot for new management to work through after the company divested its retail generics portfolio.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MAYNF: